share_log

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

phio pharmaceuticals宣佈將在第39屆腫瘤免疫治療學會議上進行演講
Phio Pharmaceuticals ·  10/24 12:00

New clinical data from Phio's on-going Phase 1b trial to be presented

來自Phio正在進行的10期試驗的新臨床數據將公佈

Marlborough, Massachusetts–(Newsfile Corp. – October 24, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new clinical data from the on-going Phase 1b clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Houston, TX from November 8-10, 2024.

馬薩諸塞州馬爾伯勒—(Newsfile Corp.,2024年10月24日)——Phio製藥公司(納斯達克股票代碼:PHIO)是一家臨床階段生物技術公司,其專有的INTASYL siRNA基因沉默技術旨在使免疫細胞更有效地殺死腫瘤細胞。該公司今天宣佈,將在癌症免疫療法協會(SITC)第39屆年會上公佈正在進行的10期臨床試驗的新臨床數據將於 2024 年 11 月 8 日至 10 日在德克薩斯州休斯敦舉行。

Presentation Details are as follows:

演示詳情如下:

Title: INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma
Abstract Number: 696
Presenting Author: Mary Spellman, M.D.
Date: Saturday November 9, 2024
Location: Exhibit Halls A and B, George R. Brown Convention Center
標題: INTASYL PH-762:針對皮膚癌的 PD-1 定向腫瘤內免疫療法
摘要編號: 696
主講作者: Mary Spellmanwand.D.
日期: 2024 年 11 月 9 日星期六
地點: 喬治 ·R· 布朗會議中心 A 和 b 展廳

About Phio Pharmaceuticals Corp.

Phio 製藥公司簡介

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.

Phio Pharmicals Corp.(納斯達克股票代碼:PHIO)是一家臨床階段的生物技術公司,專注於使用其專有的INTASYL siRNA技術對特定基因進行沉默。INTASYL 幾乎可以靶向和抑制任何具有高特異性的基因,適用於各種組織類型。INTASYL主要設計用於增強免疫細胞殺死腫瘤細胞的能力,可以在改善過繼細胞療法方面發揮關鍵作用。值得注意的是,INTASYL是唯一一種自動遞送的RNAi技術,因爲它不需要專門的配方或藥物遞送系統。

For additional information, visit the Company's website, .

欲了解更多信息,請訪問公司的網站。

Forward Looking Statements

前瞻性陳述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述。前瞻性陳述可以通過諸如 「打算」、「相信」、「預期」、「計劃」、「預期」、「建議」、「可能」、「將」、「潛在」、「設計用於」、「將」、「持續」、「估計」、「預測」、「目標」、「預測」、「可能」 等詞語來識別,儘管不是所有前瞻性陳述包含這些單詞。這些陳述僅基於我們當前的信念、預期和假設,並受固有的不確定性、風險和環境變化的影響,這些因素難以預測,其中許多是我們無法控制的。由於許多重要因素,我們的實際業績可能與前瞻性陳述中顯示的結果存在重大差異,包括但不限於通貨膨脹壓力、利率上升、經濟衰退擔憂、候選產品的開發、臨床前和臨床活動的結果、我們執行業務戰略的能力、我們與合作伙伴開發候選產品的能力以及任何此類合作的成功,時間表和持續時間包括推動我們的候選產品進入臨床開發階段、監管機構申請和批准的時機或可能性、我們在獲得批准後將候選產品商業化的努力是否成功、我們爲臨床活動以及獲得批准後用於商業用途的候選產品的能力、我們能夠建立和維持的涵蓋技術平台的知識產權的保護範圍、我們獲得未來融資的能力、市場和其他條件以及我們的年度報告中確定的條件10-K表格及隨後的10-Q表季度報告,標題爲 「風險因素」,以及公司定期向美國證券交易委員會提交的其他文件。我們敦促讀者審查這些風險因素,不要依賴任何前瞻性陳述行事,因爲實際結果可能與我們的前瞻性陳述所設想的結果有所不同。除非法律要求,否則Phio不承諾更新前瞻性陳述以反映本新聞稿發佈之日後發生的觀點、事件或情況的變化。

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

聯繫人:
菲奧製藥公司
詹妮弗菲利普斯:jphillips@phiopharma.com
公司事務

big

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論